Ye et al. [59] conducted a meta-analysis concerning XRCC1 and GSTP1 polymorphisms and prognosis with oxaliplatin-based chemotherapy in metastatic CRC. XRCC1 Arg399Gln polymorphism was significantly associated with oxaliplatin-based chemotherapy response in CRC when stable disease and disease progression were defined as nonresponse, although the association was not significant when only disease progression was considered as nonresponse. This evidence concerns the gene XRCC1 and colorectal carcinoma.